Filing Flows › Foghorn Therapeutics (FHTX) › Q1 2026 › vs Q4 2025
Foghorn Therapeutics (FHTX) Q1 2026 vs Q4 2025 (quarter over quarter)
Foghorn Therapeutics's revenue fell $6.0M (-65%) from $9.2M in Q4 2025 to $3.3M in Q1 2026.
Foghorn Therapeutics, Q1 2026: revenue $3.3M (-45% year over year), operating margin -660.3%, net loss $19.9M, operating cash flow −$25.3M. The chart draws each line against Q4 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q4 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $3.3M | $9.2M | −$6.0M | -65% |
| Other income, net | $1.7M | $2.2M | −$516K | -23% |
| Net loss | $19.9M | $21.7M | −$1.8M | -8% |
| Costs & expenses | $24.8M | $33.1M | −$8.3M | -25% |
| Operating costs | $24.8M | $33.1M | −$8.3M | -25% |
| Research & development | $18.3M | $22.0M | −$3.8M | -17% |
| General & admin | $6.6M | $6.8M | −$216K | -3% |
| Operating cash sources | $27.9M | $25.3M | $2.6M | +10% |
| Depreciation & amortization | $238K | $802K | −$564K | -70% |
| Share-based compensation | $2.4M | $2.2M | $142K | +6% |
| Cash used in operations | $25.3M | $22.3M | $3.0M | +13% |
| Net loss absorbed | $19.9M | $21.7M | −$1.8M | -8% |
| Working capital & other | $8.0M | $3.6M | $4.4M | +120% |
Questions
How much did Foghorn Therapeutics's revenue grow quarter over quarter in Q1 2026?
Foghorn Therapeutics's revenue fell $6.0M (-65%) from $9.2M in Q4 2025 to $3.3M in Q1 2026.